Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
6.3
245.16%
60%
—
20.29%
60%
—
5 Years
Score6.3
Net Growth245.16%
Net Trend60%
Net Income Consistency—
Rev Growth20.29%
Rev Trend60%
Revenue Consistency—
Ligand Pharmaceuticals Incorporated fundamental performance
Between 2020 and 2025, revenue grew from $ 163M to $ 268M and net income went from -$ 2M to $ 124M. Revenue increased in 3 of those 5 years; net income in 3.
Between 2015 and 2025, revenue grew from $ 71M to $ 268M and net income declined from $ 257M to $ 124M. Revenue increased in 7 of those 10 years; net income in 7.
Ligand Pharmaceuticals Incorporated currently holds a 20-year HDB Score of 5.5 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 293.27 | — |
1 Year2025-08-12 | $ 152.69 | 92.07% |
5 Years2021-08-12 | $ 68.03 | 331.10% |
10 Years2016-08-12 | $ 71.08 | 312.60% |
20 Years2006-08-11 | $ 22.44 | 13x |
30 Years1996-08-12 | $ 31.39 | 9x |
All Time1992-11-18 | $ 31.39 | 9x |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 | 30 Years1996-08-12 | All Time1992-11-18 |
|---|---|---|---|---|---|---|---|
| Price | $ 293.27 | $ 152.69 | $ 68.03 | $ 71.08 | $ 22.44 | $ 31.39 | $ 31.39 |
| Return | — | 92.07% | 331.10% | 312.60% | 13x | 9x | 9x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 290M | $ 197M | $ 1.35B |
| 2025 | $ 268M | $ 124M | $ 733M |
| 2024 | $ 167M | -$ 4M | $ 256M |
| 2023 | $ 131M | $ 52M | $ 170M |
| 2022 | $ 196M | -$ 33M | $ 211M |
| 2021 | $ 241M | $ 57M | $ 341M |
| 2020 | $ 163M | -$ 2M | $ 411M |
| 2019 | $ 120M | $ 629M | $ 1.06B |
| 2018 | $ 251M | $ 143M | $ 764M |
| 2017 | $ 141M | $ 12M | $ 201M |
| 2016 | $ 108M | -$ 1M | $ 141M |
| 2015 | $ 71M | $ 257M | $ 200M |
| 2014 | $ 64M | $ 12M | $ 167M |
| 2013 | $ 48M | $ 11M | $ 15M |
| 2012 | $ 31M | -$ 527K | $ 12M |
| 2011 | $ 30M | $ 10M | $ 17M |
| 2010 | $ 23M | -$ 12M | $ 22M |
| 2009 | $ 38M | -$ 1M | $ 53M |
| 2008 | $ 27M | -$ 98M | $ 80M |
| 2007 | $ 12M | $ 281M | $ 94M |
| 2006 | $ 140M | -$ 31M | $ 171M |
| 2005 | $ 176M | -$ 36M | $ 86M |
| 2004 | $ 163M | -$ 45M | |
| 2003 | $ 141M | -$ 37M | $ 99M |
| 2002 | $ 96M | -$ 32M | $ 64M |
| 2001 | $ 76M | -$ 42M | $ 37M |
| 2000 | $ 48M | -$ 72M | $ 23M |
| 1999 | $ 40M | -$ 74M | $ 47M |
| 1998 | $ 17M | -$ 117M | $ 32M |
| 1997 | $ 51M | -$ 100M | $ 62M |
| 1996 | $ 36M | -$ 37M | $ 34M |
| 1995 | $ 24M | -$ 64M | $ 16M |
| 1994 | $ 13M | -$ 27M | $ 7M |
Explore beyond LGND
You're looking at Ligand Pharmaceuticals Incorporated. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
